MIST logo

MILESTONE PHARMACEUTICALS IN

MISTNASDAQ
🏆 #4078 by market capEarnings Nov 10US Equity
$0.81▲ $0.02 (+2.05%)
Market closed · at close
🔔
Track MIST
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.0%
7d▼ 5.3%
14d▼ 9.6%
30d▼ 29.9%
ytd▼ 60.0%
1y▼ 59.7%
🏦Market Cap
$101M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
94.6%
High
💵FCF Margin
-2612.7%
Thin
⚖️P/S Ratio
43.6x
Expensive
Otter Score
72
Fair

Trading Snapshot

Day Range
$0.80 – $0.82
52-Week Range
$0.75 – $3.06
Volume
$3.26B
Avg Volume
$3.31B
Shares Outstanding
124.5M
Next Earnings
Oct 21, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$559,000
P/E Ratio
-1.2
P/S Ratio
43.6x
EPS (TTM)
$-0.61
Dividend Yield
0.00%
Dilution (1yr)
+34.8%

Why Investors Own MIST

  • ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 49% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MIST logo

MILESTONE PHARMACEUTICALS IN

MIST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
92.6%▼ −7.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$62M▲ +48.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$49M▲ +70.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
83.9M▲ +34.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15M▲ +$44M YoY
StockOtter · stockotter.space

About MILESTONE PHARMACEUTICALS IN

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$1.07
▲ +32.6% Upside
High Target$1.34
Low Target$0.90
Based on 18 analysts

Latest News & Updates

🚀
Barron’s·2h ago

MILESTONE PHARMACEUTICALS IN tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift MIST price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

MILESTONE PHARMACEUTICALS IN announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.